<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02863120</url>
  </required_header>
  <id_info>
    <org_study_id>TG-EXP-160402</org_study_id>
    <nct_id>NCT02863120</nct_id>
  </id_info>
  <brief_title>Liposomal Bupivacaine vs Adductor Canal Block in Total Knee Arthroplasty</brief_title>
  <official_title>Patient Outcomes With Periarticular Liposomal Bupivacaine Injection vs Adductor Canal Block After Primary Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Texas Orthopaedics, Sports and Rehabilitation Associates</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Texas Orthopaedics, Sports and Rehabilitation Associates</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to evaluate the outcomes of patients undergoing total knee&#xD;
      replacement with two different methods of local pain control:shots of liposomal bupivacaine,&#xD;
      a long acting anesthetic, directly into the knee during surgery or anesthetic delivered&#xD;
      continuously to the adductor canal to provide long term pain relief. The goal is to try to&#xD;
      find a standard protocol that provides the greatest pain relief for patients undergoing total&#xD;
      knee replacement.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Actual">December 2019</completion_date>
  <primary_completion_date type="Actual">December 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Length of stay (LOS, in days)</measure>
    <time_frame>Participants will be followed for the duration of their hospital stay, an expected average of 1.5 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to ambulation (in hours)</measure>
    <time_frame>2-6 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain as assessed by visual analog scale (VAS) on postoperative day 0</measure>
    <time_frame>6 hours</time_frame>
    <description>Pain levels will be determined on postoperative day 0, 1, 2, 3, 4, and 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain as assessed by visual analog scale (VAS) on postoperative day 1</measure>
    <time_frame>24 hours</time_frame>
    <description>Pain levels will be determined on postoperative day 0, 1, 2, 3, 4, and 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain as assessed by visual analog scale (VAS) on postoperative day 2</measure>
    <time_frame>48 hours</time_frame>
    <description>Pain levels will be determined on postoperative day 0, 1, 2, 3, 4, and 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain as assessed by visual analog scale (VAS) on postoperative day 3</measure>
    <time_frame>72 hours</time_frame>
    <description>Pain levels will be determined on postoperative day 0, 1, 2, 3, 4, and 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain as assessed by visual analog scale (VAS) on postoperative day 4</measure>
    <time_frame>96 hours</time_frame>
    <description>Pain levels will be determined on postoperative day 0, 1, 2, 3, 4, and 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain as assessed by visual analog scale (VAS) on postoperative day 5</measure>
    <time_frame>120 hours</time_frame>
    <description>Pain levels will be determined on postoperative day 0, 1, 2, 3, 4, and 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid consumption in oral morphine equivalents (OMEs, in milligrams)</measure>
    <time_frame>Participants will be followed for the duration of their hospital stay, an expected average of 1.5 days.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complications and adverse events</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Liposomal bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Periarticular infiltration of 20cc of liposomal bupivacaine with 10cc of normal saline and 30cc of bupivacaine HCl administered prior to cementation of knee implants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adductor canal and tibial nerve block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Preoperative tibial nerve block with 15cc bupivacaine HCl and adductor canal block with 20cc adductor canal block. Postoperative continuous adductor canal block with 550cc ropivacaine at 8cc per hour</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liposomal bupivacaine</intervention_name>
    <arm_group_label>Liposomal bupivacaine</arm_group_label>
    <other_name>Exparel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bupivacaine HCl</intervention_name>
    <arm_group_label>Adductor canal and tibial nerve block</arm_group_label>
    <arm_group_label>Liposomal bupivacaine</arm_group_label>
    <other_name>Marcaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <arm_group_label>Adductor canal and tibial nerve block</arm_group_label>
    <other_name>Naropin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <arm_group_label>Liposomal bupivacaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or non-pregnant female between the ages of 18-65&#xD;
&#xD;
          -  Patients willing and able to sign the informed consent&#xD;
&#xD;
          -  Patients able to comply with follow-up requirements including self-evaluations&#xD;
&#xD;
          -  Patients requiring a primary total knee replacement&#xD;
&#xD;
          -  Patients with a diagnosis of osteoarthritis, traumatic arthritis, or avascular&#xD;
             necrosis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Revision total knee arthroplasty&#xD;
&#xD;
          -  Bilateral total knee arthroplasty&#xD;
&#xD;
          -  Patients with inflammatory arthritis&#xD;
&#xD;
          -  Patients with a body mass index (BMI) &gt; 40&#xD;
&#xD;
          -  Allergy to ropivacaine, bupivacaine, or other local anesthetic agents&#xD;
&#xD;
          -  Current use of opioid drugs&#xD;
&#xD;
          -  Patients with a history of total or unicompartmental reconstruction of the affected&#xD;
             joint&#xD;
&#xD;
          -  Patients that have had a high tibial osteotomy or femoral osteotomy&#xD;
&#xD;
          -  Patients with neuromuscular or neurosensory deficiency, which would limit the ability&#xD;
             to assess pain levels&#xD;
&#xD;
          -  Patients with a systemic or metabolic disorder leading to progressive bone&#xD;
             deterioration&#xD;
&#xD;
          -  Patients that are immunologically compromised, or receiving chronic steroids (&gt;30&#xD;
             days), excluding inhalers&#xD;
&#xD;
          -  Patients' bone stock is compromised by disease or infection, which cannot provide&#xD;
             adequate support and/or fixation to the prosthesis&#xD;
&#xD;
          -  Patients with knee fusion to the affected joint&#xD;
&#xD;
          -  Patients with an active or suspected latent infection in or about the knee joint&#xD;
&#xD;
          -  Patients that are prisoners&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tyler D Goldberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Orthopedics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Texas Orthopedics</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>August 8, 2016</study_first_submitted>
  <study_first_submitted_qc>August 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2016</study_first_posted>
  <last_update_submitted>October 5, 2020</last_update_submitted>
  <last_update_submitted_qc>October 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bupivacaine</keyword>
  <keyword>Osteoarthritis</keyword>
  <keyword>Arthritis</keyword>
  <keyword>Joint Diseases</keyword>
  <keyword>Ropivacaine</keyword>
  <keyword>Anesthetics, Local</keyword>
  <keyword>Anesthetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

